Phosphagen. Share Discussion Threads

[spaceparallax] 11/12/2007 10:20

Received my December newsletter - makes very encouraging reading. The time for payback is getting close.

[donaferentes] 04/12/2007 18:42

Also note that under Market Cap section only ASX is mentioned. Someoe ought to write to their UK NOMAD and get them onside to keep half their investors informed better. Good operational company though for all that. But quite a way to go as page 23 shows, until US fully approves.

[suesean1] 04/12/2007 12:10

Again no rsn.

[suesean1] 04/12/2007 12:09

2 x News, have not read them yet, news letter out on psg web site plus interview on sky tv.

And

[worc0670] 21/11/2007 14:08

I'm waiting to top up at these levels too. Today may be too early though. Will wait a couple of days.......

[hopeless698] 21/11/2007 12:44

donaferents...just buy what you can at this share price and hold for the next couple of years. Nobody knows exact timescales but this will literally fly in a short period of time once the good news arrives.

[spaceparallax] 21/11/2007 09:53

My guess would be that the Nestle deal will begin to deliver towards the middle of next year. On the more significant transdermal front, I suspect that we'll have to wait patiently for the concrete clinical case to be sealed, after which we could start making serious money that could really mushroom.

All IMHO

[donaferentes] 21/11/2007 09:37

hopeless or anyone else in here - what is your guess of a realistic time scale to first operating profit for PSG? and with which products - Nestle Vitamin E or Insulin/Morphine transdermals?
TIA

[hopeless698] 21/11/2007 08:09

I can't think of a better time to buy into this company. The share price is at a low and is perfect to buy and leave for the medium term.

[rambutan2] 07/11/2007 23:02

he paid 10.7p equiv.

[spaceparallax] 07/11/2007 10:44

ironically, we see a Director BUY.

[hopeless698] 06/11/2007 16:39

sp going downwards! could be a big sell going through!

[ladybird1] 01/11/2007 13:15

spacep

That is clearly so. As usual, of course, products can look so promising but fall down on the last stages of the regulatory process. A godd 2008 is to be hoped for, as you say.

[spaceparallax] 01/11/2007 12:20

LB1,

I suspect you're right in respect of lack of urgency; that said, we are much closer now to a real commercial breakthrough, which could really unleash the share price

[ladybird1] 01/11/2007 09:55

spacep.

I've toyed with the idea of topping up, too. However, it continues to decline gently on the ASX (down 6% per the closing summary last night). Low volumes and not basically significant. but until further news probably no hurry for a couple of months and might well drift lower in that time, as historically the case.

[donaferentes] 31/10/2007 23:32

Thanks, ram

[spaceparallax] 31/10/2007 13:13

It would be good to know. I've been considering another top-up , following the recent Nestle news. Recent Sells appear to be causing the share price to drift.

[rambutan2] 31/10/2007 12:06

dona, it's our product, isp mkt it...

Distribution Alliances

International Specialty Products (ISP) –Vital ET™, globally

[donaferentes] 31/10/2007 11:53

rambutan - is this a PSG product or a rival - sorry not clear.
thanks

[rambutan2] 31/10/2007 09:08

I wonder how sales are progressing?

In an effort to expand our presence in the growing Personal Care market segment, ISP has introduced its Bio-Functional Ingredients platform. The products in this platform offer unique, clinically-proven and consumer-perceivable benefits, contributing to healthier skin. Vital ET and Allantoin, a well-known skin protectant, are the first of several new ingredients in ISP's Bio-Functional Ingredients platform.



Product Detail

VITAL ET® - Phosphorylated Tocopheryl
INCI Name
Disodium Lauriminodipropionate Tocopheryl Phosphates
DESCRIPTION
Appearance: Tan Emulsion
Solids: 37-44% in Water
pH: 5-7

Recommended Use Levels:
0.3%-3.0% Active
PROPERTIES
Vital ET® is a new and unique bio-functional complex of tocopherol phosphate that can reduce the appearance of redness and swelling on skin. Vital ET® can be used in products targeting the effects of aging and environmental stress. It is also excellent in shaving formulations because of its calming effect on the skin, anti-redness benefits, and excellent skin lubricity.
KEY BENEFITS
- Effective at reducing the appearance of redness and swelling
- Excellent skin lubricity
- Elegant skin feel
- Complementary benefits in acne related products
- Compatible with a broad range of raw materials
- Easy to formulate into oil and water based systems

APPLICATIONS
Sun Care: Sunscreens and After-Sun Products
Skin Care: Daily Use Body Creams, Anti-Acne, Shaving Products, Diaper Rash Creams and Antiperspirants
Color Cosmetics:
Foundations and Concealers

[lgw] 19/10/2007 14:57

Yes this is indeed good news :
More opportunity now that PSG have a clearer indication of the way to maximise the potential of their product than they did in 2003 ( and indeed a stronger relationship with Nestle)
Now back to sleep until the next rns.

[rambutan2] 19/10/2007 09:41

i agree, as agreement never really bought in the hoped for rev and they now have a clean sheet to try again in the largest mkt...

Harry Rosen, Phosphagenics President and CEO, said: "Nestle Nutrition, our
partner for medical foods, and Phosphagenics have recently announced a phase 2
clinical trial to establish the efficacy of our vitamin E phosphate in the
management of metabolic syndrome.

"We will now pursue alternative commercial arrangements for our vitamin E
phosphate in the dietary supplement market. Additionally, following our positive preclinical studies, termination of this agreement opens opportunities to explore and potentially reposition and leverage the use of our vitamin E phosphate in a multitude of markets, thus extracting additional value from the product."

[waldron] 19/10/2007 08:27

Phosphagenics says NBTY ends dietary supplement licence agreement




LONDON (Thomson Financial) - Melbourne-based Phosphagenics Ltd said its
dietary supplement commercial partner NBTY Inc has ended the licence agreement
between the two companies, and the termination will be effective six months
after notice.
Phosphagenics will be entitled to minimum royalties as specified in the deal
and expects minimal financial impact as the agreement was due to expire in July
2008.
It added that it will pursue alternative commercial arrangements for its
vitamin E phosphate.
In 2003, the company signed an agreement with Zila Inc for an initial five
years and granted the rights to market Phosphagenics' vitamin E phosphate in the
US, Canada and Indonesia.
NBTY acquired the agreement after it bought Zila's nutraceuticals unit in
2006.
Phosphagenics and the NBTY group, a nutrition-supplement maker, had since
been trying to amend the terms of the licence, but could not reach an agreement,
the biotechnology company said in a statement.

[e-mail]
apm/pmi/slm

[spaceparallax] 15/10/2007 09:22

And with obesity, there often follows diabetes.

[rambutan2] 14/10/2007 22:49

leading today's headlines...

Obesity 'as bad as climate risk'

Alan Johnson said a "cultural and societal shift" was needed
The public health threat posed by obesity in the UK is a "potential crisis on the scale of climate change", the health secretary has warned